Implementation and evaluation of the human papillomavirus (HPV) vaccination pilot for men who have sex with men (MSM), England, April 2016 to March 2017.
Adolescent
Adult
Age Distribution
Ambulatory Care Facilities
/ statistics & numerical data
Cross-Sectional Studies
Feasibility Studies
Health Knowledge, Attitudes, Practice
Homosexuality, Male
/ statistics & numerical data
Humans
Immunization
Male
Papillomaviridae
Papillomavirus Infections
/ epidemiology
Papillomavirus Vaccines
/ administration & dosage
Patient Acceptance of Health Care
/ statistics & numerical data
Program Evaluation
Rural Population
Urban Population
Vaccination
/ statistics & numerical data
England
HPV
MSM
human papillomavirus
immunisation
men who have sex with men
policy
sexual health
sexually transmitted infections
vaccination
vaccine
Journal
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
entrez:
28
2
2019
pubmed:
28
2
2019
medline:
17
7
2020
Statut:
ppublish
Résumé
Opportunistic human papillomavirus (HPV) vaccination for men who have sex with men (MSM) was piloted in sexual health clinics (SHC) in England between 2016 and 2018. to evaluate the pilot's first year (April 2016-March 2017) in terms of feasibility, acceptability, uptake, impact and equity and interpret the outcome in the context of wide HPV vaccination policy. Attendance and uptake data from routine SHC surveillance datasets and a cross-sectional survey administered to individuals receiving the vaccine were analysed. Among 18,875 eligible MSM, 8,580 (45.5%) were recorded as having received one HPV vaccine dose, decreasing slightly with increasing age, and uptake was higher in rural than urban areas. Survey results suggested that of those receiving the first dose of HPV vaccine, 8% were new attendees and that among those, less than 11% attended just to receive the vaccine. Of those having their first HPV vaccination, 95% indicated they would like to receive the next vaccine doses at the same clinic and 85% of patients reported accessing other services when visiting SHC for the first dose of vaccine. An opportunistic HPV vaccination programme for MSM can be delivered in an acceptable and, as far as can be evaluated, equitable manner, without major disruption to SHC and HIV clinics.
Sections du résumé
BACKGROUND
BACKGROUND
Opportunistic human papillomavirus (HPV) vaccination for men who have sex with men (MSM) was piloted in sexual health clinics (SHC) in England between 2016 and 2018.
AIM
OBJECTIVE
to evaluate the pilot's first year (April 2016-March 2017) in terms of feasibility, acceptability, uptake, impact and equity and interpret the outcome in the context of wide HPV vaccination policy.
METHODS
METHODS
Attendance and uptake data from routine SHC surveillance datasets and a cross-sectional survey administered to individuals receiving the vaccine were analysed.
RESULTS
RESULTS
Among 18,875 eligible MSM, 8,580 (45.5%) were recorded as having received one HPV vaccine dose, decreasing slightly with increasing age, and uptake was higher in rural than urban areas. Survey results suggested that of those receiving the first dose of HPV vaccine, 8% were new attendees and that among those, less than 11% attended just to receive the vaccine. Of those having their first HPV vaccination, 95% indicated they would like to receive the next vaccine doses at the same clinic and 85% of patients reported accessing other services when visiting SHC for the first dose of vaccine.
CONCLUSION
CONCLUSIONS
An opportunistic HPV vaccination programme for MSM can be delivered in an acceptable and, as far as can be evaluated, equitable manner, without major disruption to SHC and HIV clinics.
Identifiants
pubmed: 30808443
doi: 10.2807/1560-7917.ES.2019.24.8.1800055
pmc: PMC6446955
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
Cancer. 2004 Jul 15;101(2):270-80
pubmed: 15241823
Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25
pubmed: 16949997
Br J Cancer. 2007 May 7;96(9):1320-3
pubmed: 17375045
Nat Clin Pract Oncol. 2008 Jan;5(1):24-31
pubmed: 18097454
Pharmacoeconomics. 2008;26(9):733-44
pubmed: 18767894
BMJ. 2013 Apr 18;346:f2032
pubmed: 23599298
Virol J. 2013 May 01;10:137
pubmed: 23634957
J Clin Pathol. 2015 Feb;68(2):135-40
pubmed: 25410654
Lancet Infect Dis. 2015 May;15(5):565-80
pubmed: 25744474
Clin Infect Dis. 2017 Mar 1;64(5):580-588
pubmed: 28011615
Sex Transm Infect. 2018 Nov;94(7):542-544
pubmed: 28280237
Lancet. 2018 Sep 15;392(10151):913-914
pubmed: 30238882